CLX

Business Profile & Competitive Position

The Clorox Company operates in the Consumer Defensive sector, specifically the Household & Personal Products industry. It is a multinational manufacturer and marketer of consumer and professional products, with fiscal 2026 net sales of $6.7 billion and roughly 9,200 employees operating in approximately 25 countries and selling in about 95 markets. Its shelf spans well-known consumer brands such as Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while its professional arm sells under Purell, CloroxPro, and CloroxHealthcare labels.

The company’s competitive positioning is more nuanced than the brand list alone suggests. A net margin of 9.4% shows the business still converts sales into bottom-line profit, yet a P/E of 16.2 and market cap of $10.9 billion place it in a mid-tier valuation bracket relative to many large-cap consumer staples peers. The most jarring figure is the ROE of -1920.6%. ROE at that magnitude is effectively negative because shareholder equity has been compressed, distorted by cumulative losses, heavy buybacks, or balance-sheet restructuring—not because the operating business is losing money on every sale. A positive net margin paired with a deeply negative ROE implies that book value has shrunk to a very small base while earnings remain modestly positive. For a business whose moat rests on shelf space, brand loyalty, and repeat-purchase household habits, these equity dynamics are worth monitoring closely because they constrain financial flexibility and can amplify the impact of any future write-downs or acquisition integration costs.

Financial Posture

Against a recent price of $89.90 and a 50-day EMA of $88.55, CLX trades essentially in line with its near-term moving average, with an RSI of 58.4 pointing to neutral momentum. The P/E multiple of 16.2 is not extreme for a defensive staples name, but it is not a bargain valuation either, given that FY2026 diluted EPS fell 26% and organic sales also declined. The 9.4% net margin suggests the core business remains profitable, yet the combination of lower earnings and a still-mid-teens multiple means the stock is pricing in some recovery.

Balance-sheet health is the area that warrants the most scrutiny. The -1920.6% ROE signals that shareholders’ equity is minimal or negative; earnings are positive, but the denominator in the ROE calculation has collapsed. That situation can arise from aggressive share repurchases, accumulated deficits, or goodwill impairment, and it leaves the company more dependent on debt and operating cash flow to fund operations and acquisitions. The beta of 0.58 confirms the stock behaves more defensively than the broad market, which is consistent with its sector, but low equity does not remove credit or operational risk. In short, CLX looks like a stable cash-generating staples business on the income statement, but its equity base raises structural questions.

Strategic Priorities & Outlook

The company’s most recent 10-K filing outlines a clear near-term agenda. Clorox is executing its IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. Beneath those headlines sits a major operational push to complete and optimize a new enterprise resource planning (ERP) system and a broader digital transformation designed to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

Portfolio reshaping is just as important as cost structure. In April 2026, Clorox completed its acquisition of GOJO Industries, expanding its health and hygiene footprint and strengthening its business-to-business presence. The 10-K emphasizes advancing health and hygiene expansion, integrating GOJO, and growing professional and institutional markets. At the same time, the company is trying to streamline its operating model and build a more resilient organization. Notably, fiscal year 2026 was a reset year: organic sales and earnings declined, with diluted EPS down 26%, partly because ERP transition timing had pulled some sales into fiscal 2025 and partly because of macroeconomic headwinds. These are the metrics against which any turnaround narrative must be judged.

Macro & Geopolitical Exposure

As a Household & Personal Products company, Clorox faces macro exposures that are typical of consumer staples but with important twists. Input costs for plastics, resins, paper, chemicals, and agricultural commodities directly affect margins, as do freight and energy costs. Currency translation matters for a company selling in roughly 95 markets, so a stronger U.S. dollar can compress reported international revenue and earnings.

Regulatory and trade policy risk is also inherent to the industry. Cleaning and personal-care products are subject to environmental regulations, chemical safety standards, and labeling requirements that vary by country. Tariffs or trade disputes can disrupt the sourcing of raw materials or packaging, and any changes in consumer product safety rules can force reformulation or packaging redesigns. Supply-chain concentration is another classic concern: a company that sells everyday essentials must maintain extremely high service levels, so disruptions in manufacturing or distribution quickly translate into lost shelf space. These factors do not tell us what will happen to Clorox specifically, but they define the macro and policy backdrop against which the stock is valued.

Recent Developments

November 2, 2026 was an active news day for Clorox. Seeking Alpha published the Q1 2027 earnings call transcript, Zacks issued two separate reports comparing results to estimates and noting that Clorox surpassed both earnings and revenue expectations, and The Wall Street Journal reported that the company posted higher revenue and profit but trimmed its outlook because of higher costs.

The quarter itself was a substantial beat: actual EPS came in at $1.55 against an estimate of $1.07, a 44.9% positive surprise. However, the headline beats were paired with management caution. The WSJ report’s framing—that higher costs were prompting a reduced outlook—captures the tension: Clorox exceeded the market’s real expectation for Q1, but its forward guidance suggested margin and cost pressures are not yet behind it. This is a pattern investors often watch for in staples names: a near-term beat is valuable, but if it is driven by timing or mix rather than sustainable cost relief, the post-earnings reaction can be muted or even negative.

Earnings Behavior & Post-Earnings Drift

Over the last eight reported quarters, Clorox has beaten earnings estimates six times, for a beat rate of 75%. The average earnings surprise across those quarters is 11.1%, and the average 5-day price move after earnings is +3.58%, classified as an upward post-earnings drift. That headline trend suggests the market often underprices Clorox’s earnings power, but the individual quarter-to-quarter reactions are noisy.

The four most recent reports illustrate that noise clearly. On November 2, 2026, CLX beat by 44.9% with actual EPS of $1.55 versus an estimate of $1.07—the type of blowout that can reset sentiment if sustained. The prior quarter, August 3, 2026, was a much narrower beat of just 1.2% ($1.66 vs. $1.64), yet the stock jumped 6.52% the next session and 9.61% over the following five days. By contrast, the April 30, 2026 report delivered a 5.8% beat ($1.64 vs. $1.55) but the stock fell 9.67% the next day and 4.49% over five days, likely because forward guidance or cost commentary disappointed. Even the February 3, 2026 miss—actual EPS of $1.39 versus $1.43, a 2.8% negative surprise—was followed by a 2.43% next-day gain and a 5.63% five-day advance, underscoring that price reaction to Clorox reports is not purely a function of whether revenue or EPS beat.

With next earnings scheduled for February 2, 2027 after the close and the consensus EPS estimate at $1.36, the setup will be watched against both the recent $1.55 actual and the company’s trimmed full-year outlook. The unofficial consensus has room to move if management commentary on costs, GOJO integration, and ERP benefits shifts.

For a deeper dive into how institutional analysts are currently weighing these margins, the GOJO integration, and the February 2, 2027 earnings setup, see the full institutional verdict on this ticker.